The purpose of this study is to find out if tecovirimat is a safe and effective drug to treat monkeypox (mpox) in combination with standard of care (SOC). Participants will be randomly assigned to receive oral tecovirimat plus SOC or placebo plus SOC for 14 days.
Kole, Congo, The Democratic Republic of the
L'Hôpital Général de Référence de Tunda
Tunda, Congo, The Democratic Republic of the
Laboratory-confirmed monkeypox virus infection as determined by PCR obtained from blood, oropharynx, or skin lesion within 48 hours of screening
Monkeypox illness of any duration provided that the patient has at least one active, not yet scabbed, lesion
Weight ≥3 kg
Men and non-pregnant women of reproductive potential must agree to use effective means of contraception when engaging in sexual activities that can result in pregnancy, from the time of enrollment through the end of study participation. Acceptable methods of contraception include the following:
Male or female condom
Diaphragm or cervical cap with a spermicide
Stated willingness to comply with all study procedures (including required inpatient stay) and availability for the duration of the study
Ability to provide informed consent personally or by a legally or culturally acceptable representative if the patient is unable to do so
Current or planned use of a meglitinide (repaglinide, nateglinide)
Planned use of midazolam while on study drug
Severe anemia, defined as hemoglobin <7 g/dL
Current or planned use of another investigational drug at any point during study participation
Patients who, in the judgement of the investigator, will be at significantly increased risk as a result of participation in the study
Participants who are unable to safely swallow oral medications, such as those who are at risk of aspiration
Study Contact Info
Contact Listings Owner Form
Tecovirimat for Treatment of Monkeypox Virus 0 reviewsWrite Your Review
There are no reviews yet.
Write Your Review
If a participant reaches full body lesion resolution but subsequently develops at least one new lesion consistent with mpox after discharge but while still enrolled in the study, they will be eligible to make a sick visit and will be offered standard of care for mpox.